Outcomes After Percutaneous Zadek Osteotomy for Insertional Achilles Tendinopathy.

Autor:	Hall S; University of South Carolina, School of Medicine, Columbia, SC, USA., Schipper ON; Anderson Orthopaedic Clinic, Arlington, VA, USA., Kaplan JRM; Duke University Orthopedics, Durham, NC, USA., Johnson AH; Hospital for Special Surgery, New York, NY, USA., Gonzalez TA; University of South Carolina, School of Medicine, Columbia, SC, USA.; Prisma Health Orthopedics, Lexington, SC, USA., Vulcano E; Columbia University Division of Orthopedics at Mount Sinai Medical Center, Miami Beach, FL, USA.
Jazyk:	angličtina
Zdroj:	Foot & ankle international [Foot Ankle Int] 2024 Sep; Vol. 45 (9), pp. 931-939. Date of Electronic Publication: 2024 Sep 01.
DOI:	10.1177/10711007241252803
Abstrakt:	Background: Surgical treatment of insertional Achilles tendinopathy (IAT) historically consists of Achilles tendon debridement with reattachment and excision of the posterosuperior calcaneal prominence with or without a gastrocnemius recession. Zadek osteotomy (ZO) is an alternative to an open midline splitting approach. The purpose of this study was to analyze patient-reported outcomes and complications after percutaneously performed ZO with minimum 2 years' follow-up. Methods: One hundred eight cases treated with percutaneous ZO with a minimum 2-year follow-up were retrospectively reviewed. Postoperative complications and patient satisfaction were evaluated. Foot Function Index (FFI) and visual analog scale (VAS) scores were recorded at preoperative and follow-up appointments to measure patients' functional outcomes and pain, respectively. Results: Mean follow-up was 41.2 months (range, 24-65). Mean age was 51.8 years (range, 28-81). The mean FFI score improved from 56.1 (range, 47-88) to 11.0 (range, 7-59) postoperatively ( P < .001). The mean VAS score improved from 7.7 (range, 5-10) to 0.4 (range, 0-7) postoperatively ( P < .001). The overall complication rate was 3.8% (n = 4). Of 104 cases, 98.1% of patients said they were satisfied with their procedure (n = 102) when asked if they were satisfied with their ZO and recovery. Conclusion: We found the percutaneous ZO to be a safe and effective intervention for treatment of IAT. At a minimum of 2-year follow-up, this intervention is associated with minimal complications, improved function, reduced pain, and a high rate of patient satisfaction. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Oliver N. Schiper, MD reports royalties or licenses and consulting fees from Treasce Medical Concepts, Vilex, Exactech, and Enovis. Jonathan R. M. Kaplan, MD, reports royalties or licenses and consulting fees from Artelon, Edge Surgical, Exactech, Surgebright, and Enovis. A. Holly Johnson, MD, reports royalties or licenses from Novastep and Treace Medical Concepts. Tyler A. Gonzalez, MD, MBA, reports royalties or licenses and consulting fees from Treace Medical Concepts, Surgical Fusion Technologies, Vilex; consulting fees from Stryker, Surgebright, and Enovis. Ettore Vulcano, MD, reports royalties or licenses and consulting fees from Novastep, Vilex, and Treace Medical Concepts. Disclosure forms for all authors are available online.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu